Donald Buchsbaum, Ph.D. – Program Co-Leader
Troy Randall, Ph.D.– Program Co-Leader
The objectives of the Inflammation, Immunology, and Immunotherapeutics (III) Program are to build on to and accelerate research in basic immunology and interactions of cancer and the immune system that have led over the past few years to an explosive increase in the successes of immunotherapeutic modalities in cancer. This will be achieved by developing novel therapeutic approaches for the treatment of leukemia/lymphoma and solid tumors and by understanding and exploiting the basic biology of the immune system’s responses to cancers.
In order to strengthen our research efforts in this area and in response to our External Advisory Committee, we merged most of the previous members in the former Virology Program with the Tumor Immunology Program in 2012 to create the Inflammation, Immunology and Immunotherapeutics Program. This merger has maximized the synergy between the disciplines of virology and immunology and recognizes the evolving role of inflammation in cancer etiology.
The specific aims of the program are:
- To investigate the mechanism by which inflammation contributes to the etiology of cancer;
- To advance basic immunobiology research involving inflammation and T- and B-cell immunology that contributes to understanding of inflammation-immune system tumor interactions to provide novel immunodiagnostics and immunotherapeutics;
- To identify viral mechanism of immunosuppression and neoplasia;
- To develop novel approaches for the treatment of cancer utilizing targeted immunotherapy and antibody specificity to deliver apoptotic stimuli, drugs, or radioisotopes to tumors in animal models and humans, and to develop cancer vaccines.
The program is and will study the evolving role of inflammation in cancer, conduct innovative studies into the relationship of inflammatory bowel disease, the microbiome, immune system, and development of cancer. The program will continue its investigations in regards to HPV vaccines in collaboration with Johns Hopkins University through the joint Cervical Cancer SPORE.